Abstract
Delivery of type I interferon (IFN) subtypes by intramuscular inoculation of mice with a recombinant mammalian expression vector encoding IFN stimulates the immune response. Such immunomodulation drives towards a Th1-like response. The degree of stimulation of the immune response was influenced by several parameters of the naked deoxyribonucleic acid (DNA) vaccination protocol. Pretreatment of mice with bupivacaine increased transgene expression in situ. The specific subtype gene of type I IFN, the DNA concentration, the combined use of two or more subtypes, and the timing of the DNA immunisations were all found to influence the level of efficacy of IFN gene therapy in a mouse model for cytomegalovirus (CMV) infection and disease. In addition, adjuvant therapy, using type I IFN genes, for DNA virus vaccination (CMV glycoprotein B) enhanced viral-specific immunity and reduced the severity of myocarditis in mice. Thus, type I IFN gene therapy has potent adjuvant properties when delivered as DNA and can be used to regulate virus infection and disease via pleiotropic actions in the stimulation of immune responses.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Woodruff, J. F. (1980) Viral myocarditis, a review. Am J. Pathol. 101, 427ā479.
Endresz, V., Burian, K., Berencsi, K., Gyulai, Z., Kari, L., Horton, H., et al. (2001) Optimizsation of DNA immunization against human cytomegalovirus. Vaccine 19, 3972ā3980.
Danko I. and Wolff J. A. (1994) Direct gene transfer into muscle. Vaccine 12, 1499ā1502.
Rhodes, G. H., Dwarki, V. J., Abai, A. M., Felgner, J., Felgner, P. L., Gromkowski, S. H., et al. (1993) Injection of expression vectors containing viral genes induces cellular, humoral, and protective immunity, in Vaccines 93 (Channock, R. M., Brown, F., Ginsberg, H. S., Norby, E., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 137.
Biron, C. A. (1998) Role of early cytokines, including alpha and beta interferons (IFN-Ī±/Ī²), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10, 383ā390.
Foster, G. and Finter, N. B. (1998) Are all type I human interferons equivalent? J. Vitral Hepatitis 5, 143ā152.
Bartlett, E. J., Cull, V. S., Mowe, E. N., Mansfield, J. P. and James, C. M. (2003) Optimisation of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection. Biol. Proced. Online 5, 43ā52.
Bartlett, E. J., Cull, V. S., Brekalo, N. L., Lenzo, J. C., and James, C. M. (2002) Synergy of type I interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infections. Immunol. Cell Biol. 80, 425ā435.
Cull, V. S., Broomfield, S., Bartlett, E. J., Brekalo, N. L., and James, C. M. (2002) Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Ther. 9, 1369ā1378.
Yeow, W. S., Lawson, C. M., and Beilharz, M. W. (1998) Antiviral activities of interferon-Ī± subtypes in vivo. J. Immunol. 160, 2932ā2939.
Carr, D. J. J., Al-Khatib, K., James, C. M., and Silverman, R. (2003) Interferon beta suppresses herpes simplex virus type I replication in trigeminal ganglion cells through a RNase L-dependent pathway. J. Neuroimmunol. 141, 40ā46.
Harle, P., Cull, V., Agbaga, M.-P., Silverman, R., Williams, B. R., James, C., et al. (2002) Differential effect of murine type I IFN transgenes in antagonizing HSV-1 replication. J. Virol. 76, 6558ā6567.
Harle, P., Cull, V., Guo, L., Papin, J., Lawson, C., and Carr, D. (2002) Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection. Antiviral Res. 56, 39ā49.
Cull, V. S., Tilbrook, P. T., Bartlett, E. J., Brekalo, N. L., and James, C. M. (2003) Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood 101, 2727ā2735.
Bartlett, E. J., Lenzo, J. C., Sivamoorthy, S., Mansfield, J. P., Cull, V. S., and James, C. M. (2004) Type I IFN-Ī² gene therapy suppresses cardiac CD8+ T-cell infiltration during autoimmune myocarditis. Immunol. Cell Biol. 82, 119ā126.
Cull, V. S., Bartlett, E. J., and James, C. M. (2002) Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunol. 106, 428ā437.
Lenzo, J. C., Mansfield, J. P., Sivamoorthy, S., Cull, V. S., and James, C. M. (2003) Cytokine expression in murine cytomegalovirus-induced myocarditis: modulation with interferon-Ī± therapy. Cell. Immunol. 223, 77ā86.
Hilkens, C. M., Schlaak, J. F., and Kerr, I. M. (2002) Molecular analysis of responses to interferon-alpha subtypes in human T cells and dendritic cells. J. Interferon Cytokine Res. 22, S56.
Vitadello, M., Schiaffino, M. V., Picard, A., Scarpa, M., and Schiaffino, S. (1994) Gene transfer in regenerating muscle. Human Gene Ther. 5, 11ā18.
Danko, I. and Wolff, J. A. (1994) Direct gene transfer into muscle. Vaccine 12, 1499ā1502.
Lenzo, J. C., Fairweather, D., Cull, V., Shellam, G. R., and Lawson, C. M. (2002) Characterisation of murine cytomegalovirus myocarditis: cellular infiltration of the heart and virus persistence. J Mol. Cell. Cardiol. 34, 629ā640.
Prudāhomme, G. J., Lawson, B. R., Chang, Y., and Theofilopoulos, A. N. (2001) Immunotherapeutic gene transfer into muscle. Trends Immunol. 22, 149ā155.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2005 Humana Press Inc.
About this protocol
Cite this protocol
James, C.M., Bartlett, E.J., Mansfield, J.P., Cull, V.S. (2005). Interferon Subtype Gene Therapy for Regulating Cytomegalovirus Disease. In: Carr, D.J.J. (eds) Interferon Methods and Protocols. Methods in Molecular Medicineā¢, vol 116. Humana Press. https://doi.org/10.1385/1-59259-939-7:207
Download citation
DOI: https://doi.org/10.1385/1-59259-939-7:207
Publisher Name: Humana Press
Print ISBN: 978-1-58829-418-0
Online ISBN: 978-1-59259-939-4
eBook Packages: Springer Protocols